

Case Reports

Brucellosis associated with thrombocytopenia

Iftikhar Hussein, MCPS, Bindiganavale N. Gokul, MD, Alfred Paul, MD.

ABSTRACT

Brucellosis is a zoonotic disease and is endemic in Saudi Arabia. Many hematological complications have been reported. We report a case of selective thrombocytopenia in an expatriate from Bangladesh. Patient responded well to antibrucella and steroid treatment.

Keywords: Brucellosis, Brucella, Thrombocytopenia.

Saudi Medical Journal 2000; Vol. 21 (9): 877-879

Thrombocytopenia is a subnormal number of platelets in circulating blood. It may result from deficient production, accelerated destruction and abnormal pooling of platelets within the body. Accelerated platelet destruction is the most common cause of thrombocytopenia.¹ When the rate of platelet destruction exceeds the rate of platelet production thrombocytopenia results. Brucella can rarely cause selective thrombocytopenia by primary or immunological mechanism of platelet destruction.² We have discussed a case of brucellosis with thrombocytopenia and its management in a person from Bangladesh. Though there have been reports of sporadic cases of brucellosis from the Indian subcontinent, essentially it is not endemic in these regions.

Case Report. An Asian expatriate male farmer aged 26 years hailing from Bangladesh was admitted through Emergency Room for complaints of bleeding from gums of 2 days duration and pain in knee joints. He had been living in the Kingdom for the past one and a half years. There was no previous history of similar complaints, no history of skin rash or drug intake in recent days. He was febrile with temperature of 39 degrees celsius. On examination,

the knee joints were not swollen and joint movements were painful. There was no lymphadenopathy or liver enlargement. Spleen was palpable. There was no purpuric or echymotic areas seen on admission. Purpuric spots developed later in the ward. Other systemic examination was unremarkable. On admission Hemoglobin was 12.4 gm/dl, WBC was 5700/mm³, Platelets 12000/mm³. However Prothrombin time and partial thromboplastin time were normal. Bleeding time was prolonged.

Other laboratory investigations were as follows: RBC was present in urine, stool was positive for occult blood and liver function tests were normal. Brucella antibody titer as estimated by standard agglutination test was over 1:1280. Bleeding time was more than 12 minutes. LE latex agglutination test was negative. Protein electrophoresis showed hypergammaglobulinemia. Bone marrow aspiration showed a normal picture with increased megakaryocytes (Figure 1). Urine and blood culture did not reveal any growth. Ultrasound abdomen revealed moderate splenomegaly. All relevant blood chemistry results were within normal limits.

Antibrucella treatment was started with Doxycycline and Rifampicin. High dose of Prednisolone 60 mg/day was started. On noting that

From the Department of Hematology, (Hussein), Department of Microbiology, (Gokul), Department of Medicine, (Paul), Midhnab General Hospital, Al Midhnab, Al Qassim, Kingdom of Saudi Arabia.

Received 28th February 2000. Accepted for publication in final form 14th May 2000.

Address correspondence and reprint request to: Dr. Iftikhar Hussein, Hematologist & Blood Bank Officer, Midhnab General Hospital, PO Box 253, Al Midhnab, Al Qassim, Kingdom of Saudi Arabia. Tel. 06 342 2206/342 2222 Ext. 188, 189. Fax. 06 342 1325.




Figure 1 - Photomicrograph of bone marrow smear from the patient showing normal cellular picture.

the patient had severe thrombocytopenia he was transfused with two units of platelets soon after admission. However a repeat platelet count showed only $10,000/\text{mm}^3$. The next day he was transfused with another three units of platelets. But the platelet count remained the same implying platelet destruction in circulation. Five days following admission his hemoglobin came down to 8.3 gm/dl. He was transfused with two units of packed RBC. Immunoglobulin injection was given in a dose of 400 mg/kg per day for 5 days. Prednisolone was continued for 10 days. Patient started improving with this treatment as evidenced by improved platelet count and hemoglobin. After 10 days prednisolone dosage was tapered off. He was discharged after a stay of 20 days.

Patient attended follow-up clinic after one month and was found to be completely asymptomatic. The laboratory investigations at this time showed platelets $330,000/\text{mm}^3$ and WBC $10,300/\text{mm}^3$ with all other biochemistry parameters within normal limits.

Discussion. Thrombocytopenia is a rare complication of brucellosis. *Brucella* can produce many hematological complications.³⁻⁹ According to one study by al Eissa et al, thrombocytopenia accounts for 5% of all hematological complications in brucellosis.⁸ Brucellosis is usually diagnosed by seroconversion from negative to positive or a rising agglutinin titer in the serum. An agglutination titer of over 1:160 in a symptomatic patient is also considered diagnostic in endemic areas. *Brucella* culture is the most definitive method of diagnosis of brucellosis, but culture is rarely positive because of the fastidious nature of the organism and also needs prolonged incubation.

Thrombocytopenia may be because of endotoxin release by the organism which may give rise to

disseminated intravascular coagulation. Endotoxin initiates coagulation by activating Hageman factor of intrinsic system and by causing the release of a monocyte factor which triggers the extrinsic system. The monocytes expose a tissue factor which is glycoprotein in nature, on their membrane following direct stimulation by bacterial products. Endotoxin can also cause disturbances in blood cells including platelets giving rise to thrombocytopenia. This action combined with anticoagulant action of fibrin degradation products accentuates bleeding tendency caused by disseminated intravascular coagulation (DIC).¹⁰ Anyhow in this patient the coagulation profiles were within normal limits.

In one study platelet associated IgG level was increased by 46% in patients with gram negative septicemia, suggesting an immunological mechanism.¹¹ This may explain hypergammaglobulinemia leading to accelerated platelet destruction in our case, and to a certain extent splenomegaly, since spleen is the site of destruction of platelets. However brucellosis by itself can cause splenomegaly without thrombocytopenia. In this case the combined factors of brucellosis and thrombocytopenia may have contributed to splenomegaly.

Patients with thrombocytopenia due to brucellosis respond well to anti brucella and steroid treatment. A combination of Doxycycline and Gentamicin¹² or Rifampicin with Tetracycline or Doxycycline for at least 6 weeks should be given. In view of immunological origin of thrombocytopenia, this case was treated with high dose of corticosteroids and intravenous immunoglobulin injections. Steroid and immunoglobulin therapy have been described to be useful in cases of thrombocytopenia.¹³ At times immunoglobulin therapy is recommended as the treatment of choice with a five day course.

The mode of action of immunoglobulin in the treatment of thrombocytopenia is not completely understood.¹³ However, it has been suggested that mononuclear-macrophage system - FC - receptor blockade and immune modulation with increase in T-suppressor cells, reversal of the helper/suppressor ratio and reduced B-cell function are likely to be major factors in the mechanism.¹⁴ Splenectomy as a treatment in refractory thrombocytopenia has been reported with various degrees of success but is controversial and may be harmful in areas where tuberculosis and malaria are endemic.¹⁵

During the past 10 years, at this hospital this was the first case of brucellosis associated with symptomatic thrombocytopenia.

Acknowledgments. We thank Dr. Khurshid Malik, Hematologist, KFSH, Buraidah for helping in acquiring the photomicrograph of bone marrow smear. The authors extend a warm and sincere thanks to Ms. Suja Issac for her secretarial help.

References

1. Lee GR, Bithell TC, Foerster J, Athews JW, Lukens JN, editors. In: Wintrobe's clinical hematology. 9th edition. Pennsylvania: Lea & Febiger; 1993; 1325.
2. Erb BD. Thrombocytopenic purpura accompanying brucellosis: A case report with demonstration of granuloma in the bone marrow. *J Tenn Med Assoc* 1966; 59: 876.
3. Todd KH, Lyde PD. Brucellosis and thrombocytopenic purpura. Case report and review. *Tex Med* 1989; 85: 37-38.
4. Crosby E, Llosa L, Miro Quesada M, Carrillo C, Gotuzzo E. Hematologic changes in brucellosis. *J Infect Dis* 1984; 150: 419-424.
5. Benecos P, Spingou T, Galanakis E, Lapatsanis PD. Thrombocytopenic purpura secondary to brucellosis (letter). *Eur J Pediatr* 1998; 157: 698.
6. Akdeniz H, Irmak H, Seckinli T, Buzgan T, Demiroz AP. Hematological manifestations in brucellosis cases in Turkey. *Acta Med Okayama* 1998; 52: 63-65.
7. Benjamin B. Acute thrombocytopenic purpura in childhood brucellosis. *Ann Trop Paediatr* 1995; 15: 189-192.
8. Al-Eissa Y, al Nasser M, Haematological manifestations of childhood brucellosis. *Infection* 1993; 21: 23-26.
9. Benjamim B, Annobil SH. Childhood brucellosis in Southwestern Saudi Arabia: A 5 year experience. *J Trop Pediatr* 1992; 38: 167-172.
10. Walter JB, Talbot IC, editors. In: Walter & Israel General Pathology. 7th edition. New York: Churchill Livingstone; 1996. p. 153.
11. Kelton JG, Neame PB, Gaudie J, Hirsh J. Elevated platelet associated IgG in thrombocytopenia of septicaemia. *New Eng J of Med* 1979; 300: 760-764.
12. Sanford JP, Gilbert DN, Gerberding JL, Sande MA, editors. In: Guide to antimicrobial therapy. Dallas, Texas: Antimicrobial Therapy; 1994. p. 31.
13. Hoffbrand AV, Lewis SM editors. In: Post graduate Hematology. 3rd ed. London: Heinemann Professional Publishing Limited; 1989. p. 608.
14. Manoharan A. Treatment of refractory idiopathic thrombocytopenic purpura in adults (clinical annotation). *Br J Haematol* 1991; 79: 143-147.
15. Najean Y, Dufour V, Rain JD, Toubert ME. The site of platelet destruction in thrombocytopenic purpura as a predictive index of the efficacy of splenectomy. *Br J Haematol* 1991; 79: 271-276.